Compare CVS Health Corp (CVS) vs Funko Inc (FNKO) Price & Performance

CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.

The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.

Funko (FNKO) trades at $5.88, up 11.36% today, with strong technical momentum showing bullish signals across moving averages and oscillators. The company reported improved Q2 2026 results with net sales up 7% to $207.7 million and raised adjusted EBITDA guidance, though full-year 2025 showed a net loss of $67.36 million on $908.21 million revenue. Analyst sentiment is mixed with 42.9% buy ratings, while institutional ownership remains stable.

The outlook suggests potential recovery with recent earnings beats and strategic hires, but risks include persistent negative margins, high debt levels at 32.89% debt-to-asset ratio, and competitive pressures in the collectibles market. Valuation appears reasonable with P/S of 0.35 and EV/EBITDA of 6.41, offering upside if turnaround continues.